Lymphomatoid papulosis while on efalizumab

Leo, Angela M.; Ermolovich, Tanya

doi:10.1016/j.jaad.2008.12.010

Cited by 8 publications

(3 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This raises an important question: is this patient predisposed to multiple coexisting hematologic/lymphoproliferative malignancies, or are there other complicating factors at play such as his treatment for his known CLL? In the past, several immune suppressant medications have been implicated as a possible cause of LyP . Some people have argued that composite lymphomas might have an underlying viral pathogenesis.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

A unique case of concurrent chronic lymphocytic leukemia/small lymphocytic lymphoma and lymphomatoid papulosis in the same biopsy

et al. 2015

View full text Add to dashboard Cite

Chronic lymphocytic leukemia (CLL/SLL) is the most common leukemia in the western world and its cutaneous dissemination a very uncommon phenomenon. Lymphomatoid papulosis (LyP) is a CD30+ lymphoproliferative disorder characterized by chronic, recurrent and self healing skin lesions. Up to 20% of patients with LyP have a coexistent lymphoma. While the association between the two entities has been reported, their coexistence has never been documented. We describe a 74-year-old man with known CLL and thrombocytopenia who presented with a 2 year history of recurrent nodules and plaques to both arms and legs that resolved within 4-6 weeks after administration of rituximab and bendamustin for his CLL treatment. His biopsies showed an atypical lymphoid infiltrate, composed of large and pleomorphic cells with a nodular and interstitial pattern in a background of eosinophils. Immunohistochemical staining revealed a pattern of two separate yet coexisting neoplastic processes; a large CD30 positive T-cell lymphoproliferative disorder, while the other one was diagnostic of a neoplastic B-cell process (leukemia cutis). A diagnosis of coexistent LyP and cutaneous involvement by CLL/SLL was rendered. The simultaneous presence of both disorders can be a pitfall in the differential diagnosis of large cell lymphomas, such as Richter's transformation of CLL/SLL.

show abstract

Section: Discussionmentioning

confidence: 99%

“…In the past, several immune suppressant medications have been implicated as a possible cause of LyP. 8,47 Some people have argued that composite lymphomas might have an underlying viral pathogenesis. But most of these theories are far to be confirmed.…”

Section: Discussionmentioning

confidence: 99%

A unique case of concurrent chronic lymphocytic leukemia/small lymphocytic lymphoma and lymphomatoid papulosis in the same biopsy

et al. 2015

View full text Add to dashboard Cite

show abstract

“…The increase in the size of lesions could potentially be linked to genetic mutations affecting the growth inhibitory function of the transforming growth factor-b type I receptor in CD30-positive tumor cells [13]. Additional factors that have been linked in the proliferation of cells include environmental stimuli like as radiation, as well as pharmaceutical agents including fingolimod, infliximab, adalimumab, and efalizumab [14,15,16,17,18,19,20]. Research studies have explored the phenomenon of spontaneous regression in LyP and have focused on the interaction between CD30 and its ligand.…”

Section: Epidemiologymentioning

confidence: 99%

Pediatric lymphomatoid papulosis – a case report and management considerations

Dec,

Arasiewicz

2024

Ann. Acad. Med. Siles.

View full text Add to dashboard Cite

<i>Lymphomatoid papulosis</i> (LyP) jest rzadką chorobą skóry, najczęściej obserwowaną u dorosłych, a jej występowanie w populacji pediatrycznej jest niezwykle rzadkie. W pracy przedstawiono przypadek 6-letniego dziecka płci męskiej, u którego stwierdzono cechy kliniczne i histopatologiczne zgodne z rozpoznaniem LyP. Na skórze pacjenta obserwowano liczne rumieniowe grudki zlokalizowane na tułowiu i kończynach, a towarzyszył im łagodny świąd. Zmiany chorobowe pojawiały się nawrotowo, następnie ustępowały i zmieniały morfologię. W badaniu przedmiotowym nie stwierdzono limfadenopatii ani objawów ogólnoustrojowych. W badaniu histopatologicznym w skórze właściwej stwierdzono gęsty naciek limfocytów atypowych z hiperchromatycznymi i nieregularnymi jądrami komórkowymi. Analiza immunohistochemiczna potwierdziła ekspresję CD30 w naciekających komórkach, co potwierdza rozpoznanie LyP. W celu złagodzenia świądu i stanu zapalnego podawano miejscowo glikokortykosteroidy, chociaż uzyskano jedynie minimalne złagodzenie objawów. Korzystne efekty fototerapii wąskopasmowej UVB 311 obserwowano przez cztery miesiące. Niemniej jednak po zaprzestaniu leczenia zaobserwowano ponowne pojawienie się zarówno zmian guzkowych, jak i mniejszych zmian grudkowych. W związku z tym rozpoczęto schemat terapeutyczny polegający na podawaniu metotreksatu w dawce 10 mg raz na tydzień. Leczenie LyP różni się zależnie od ciężkości zmian i objawów u pacjenta. Decyzje dotyczące leczenia należy dokładnie rozważyć ze względu na stosunkowo łagodny charakter choroby. Rozpoznanie LyP u dzieci i młodzieży stanowi wyzwanie ze względu na rzadkość występowania choroby i możliwość błędnego rozpoznania tej jednostki chorobowej z chłoniakami złośliwymi. Histopatologia i immunohistochemia odgrywają kluczową rolę w odróżnianiu LyP od bardziej agresywnych jednostek chorobowych.

show abstract

Current awareness: Pharmacoepidemiology and drug safety

2010

Pharmacoepidemiology and Drug

View full text Add to dashboard Cite

In order to keep subscribers up‐to‐date with the latest developments in their field, John Wiley & Sons are providing a current awareness service in each issue of the journal. The bibliography contains newly published material in the field of pharmacoepidemiology and drug safety. Each bibliography is divided into 23 sections: 1 Reviews; 2 General; 3 Anti‐infective Agents; 4 Cardiovascular System Agents; 5 CNS Depressive Agents; 6 Non‐steroidal Anti‐inflammatory Agents; 7 CNS Agents; 8 Anti‐neoplastic Agents; 9 Haematological Agents; 10 Neuroregulator‐Blocking Agents; 11 Dermatological Agents; 12 Immunosuppressive Agents; 13 Autonomic Agents; 14 Respiratory System Agents; 15 Neuromuscular Agents; 16 Reproductive System Agents; 17 Gastrointestinal System Agents; 18 Anti‐inflammatory Agents ‐ Steroidal; 19 Teratogens/fetal exposure; 20 Antidiabetic Agents; 21 Contrast Agents; 22 Bone Conservation Agents; 23 Others. Within each section, articles are listed in alphabetical order with respect to author. If, in the preceding period, no publications are located relevant to any one of these headings, that section will be omitted.

show abstract

Lymphomatoid papulosis while on efalizumab

Cited by 8 publications

References 5 publications

A unique case of concurrent chronic lymphocytic leukemia/small lymphocytic lymphoma and lymphomatoid papulosis in the same biopsy

A unique case of concurrent chronic lymphocytic leukemia/small lymphocytic lymphoma and lymphomatoid papulosis in the same biopsy

Pediatric lymphomatoid papulosis – a case report and management considerations

Current awareness: Pharmacoepidemiology and drug safety

Contact Info

Product

Resources

About